| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |